WO2002097066A2 - Human vascular progenitor cells - Google Patents
Human vascular progenitor cells Download PDFInfo
- Publication number
- WO2002097066A2 WO2002097066A2 PCT/IT2002/000347 IT0200347W WO02097066A2 WO 2002097066 A2 WO2002097066 A2 WO 2002097066A2 IT 0200347 W IT0200347 W IT 0200347W WO 02097066 A2 WO02097066 A2 WO 02097066A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell suspension
- antigen
- human
- vascular
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title claims abstract description 44
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 39
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 37
- 210000000709 aorta Anatomy 0.000 claims abstract description 35
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 108010035532 Collagen Proteins 0.000 claims abstract description 10
- 102000008186 Collagen Human genes 0.000 claims abstract description 10
- 229920001436 collagen Polymers 0.000 claims abstract description 10
- 239000011159 matrix material Substances 0.000 claims abstract description 8
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 129
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 59
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 59
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 36
- 210000002889 endothelial cell Anatomy 0.000 claims description 30
- 230000003511 endothelial effect Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 239000006285 cell suspension Substances 0.000 claims description 19
- 210000004185 liver Anatomy 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 11
- 238000002955 isolation Methods 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 244000309466 calf Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 4
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 230000003966 vascular damage Effects 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 102000013925 CD34 antigen Human genes 0.000 claims 5
- 108050003733 CD34 antigen Proteins 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 21
- 102100040120 Prominin-1 Human genes 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 108010047303 von Willebrand Factor Proteins 0.000 description 14
- 102100036537 von Willebrand factor Human genes 0.000 description 14
- 229960001134 von willebrand factor Drugs 0.000 description 14
- 239000011324 bead Substances 0.000 description 12
- 210000003038 endothelium Anatomy 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 9
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 8
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 8
- 230000004862 vasculogenesis Effects 0.000 description 8
- 210000000648 angioblast Anatomy 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001656 angiogenetic effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 108010005465 AC133 Antigen Proteins 0.000 description 1
- 102000005908 AC133 Antigen Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108010054176 apotransferrin Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003114 pinocytic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000001604 vasa vasorum Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Definitions
- the present invention relates to human vascular progenitor cells obtainable by /isolation from a tissue selected from explants of human foetal aorta, human liver and human foetal heart .
- these cells are capable of forming new capillary-like vascular structures ex vivo.
- a subject of the invention is therefore human vascular progenitor cells as defined in Claim 1.
- the cells of the invention are also capable of being expanded in vitro whilst remaining in an undifferentiated form, which renders them particularly suitable for use in a series of medical applications which provide for the regeneration and/or repair of vascular structures or tissues.
- progenitor cells of the invention were first of all isolated from human foetal aorta explants in the course of experiments directed towards studying the ability of the human foetal aorta to give rise to new vascular structures in vitro. These progenitor cells were then also isolated from human foetal liver and heart .
- a second subject of the invention is therefore a method of isolating vascular progenitor cells as defined in Claim 5.
- Another subject of the invention is therefore a method of forming new vascular structures as defined in Claim 9.
- Histological and immunohistochemical analyses were conducted to characterize the embryonic aortic tissue before culture in vitro in collagen gel .
- the embryonic aorta walls consisted of an endothelial lining, a internal elastic lamina, and several layers of spindly mesenchymal cells . These cells were arranged in compact fascicles and had ultrastructural features of poorly differentiated smooth muscle, including small bundles of myofilaments surrounded by elastic fibres. At this time of the embryonic development, vasa vasorum were absent .
- CD34 an antigen typically expressed in endothelial progenitor cells but also in stem cells of other origins, clearly showed that not only the lumen but also the more peripheral/para-aortic cells expressed this antigen.
- CD34 seemed to be expressed by the para-aortic tissue whereas, in several sections of different rings, it seems to be constitutively and specifically expressed by the external cells of the aortic wall, suggesting that it is not, or not only, a para-aortic cell feature.
- the external cell layer furthermore showed a strong reactivity with antibodies for the vascular endothelial growth factor receptor 2 (VEGFR2) , also known as "Flk-1", another marker of endothelial immaturity, which was also expressed by endothelial cells lining the lumen.
- VEGFR2 vascular endothelial growth factor receptor 2
- the cellular phenotype ' of the cords and capillary tubes arising from aortic rings was investigated by light microscopy, immunohistochemistry, and electron microscopy.
- the outgrowths consisted of mesenchymal spindle cells, sometimes forming aggregates with central necrotic cores. Incipient formation of capillary-like structures was often evident in areas where mesenchymal cells were densely packed. Cohesive cells with abundant cytoplasm and prominent nuclei lined the capillary-type lumen of these outgrowths. These endothelial-like cells tended to form delicate networks of long straight channels which sometimes branched at an acute angle. Immunohistochemical analysis showed that all of the cells lining the channels stained strongly for CD31 and CD34. They were also immunoreactive for vWF, though less strongly. The surrounding mesenchymal cells, which were not organized in vascular structures, were consistently negative for all of these markers .
- the cells forming the neovessels as well as the endothelial cells lining the lumen stained strongly for Flk- l/VEGFR-2.
- the micro-vessels seemed to originate both from the internal endothelial layer and from the periphery of the aortic section. This phenomenon was recorded in approximately 1 of 20 sections analyzed. In a very large number of histological sections, in fact, the most of neovascular proliferation occurred primarily in the outer aspects of the aortic rings whereas, in a very limited number of cases, it seemed to originate in the endothelial lining of the aortic lumen.
- vasculogenesis in fact consists of the de novo formation of new blood vessels from undifferentiated precursors or angioblasts.
- the outgrowth which originated from the aorta was composed of an admixture of primitive mesenchymal cells, endothelial-lined neovessels, and cells with a mixed mesenchymal/endothelial phenotype, suggesting differentiation of the mesenchyme into endothelium.
- the lining of the neovessels was composed of differentiated endothelial cells connected by junctional complexes.
- the endothelial cells exhibited a well-defined luminal/abluminal polarity and rested on a thin and discontinuous basal lamina.
- the endothelial cytoplasm contained abundant rough endoplasmic reticulum with focally dilated cisternae, Golgi complexes, pinocytotic vesicles, mitochondria, free ribosomes, and secondary lysosomes including osmiophilic myelin figures.
- Immature mesenchymal cells contained abundant glycogen, mitochondria, and bundles of microfilaments with fusiform densities which were particularly noticeable in subplasmalemmal locations.
- Cells with a mesenchymal/endothelial transitional phenotype tended to align to form longitudinal ordered structures and to establish junctional connections with one another. This caused the separation of newly formed luminal spaces from the surrounding cellular matrix. Cells sequestrated within the vascular lumina as a result of these morphogenetic changes lost their anchorages to the surrounding matrix and died, leaving behind cytoplasmic debris that was eventually found within the differentiated neovessels.
- a cell suspension of freshly-dissected foetal aortas was used to isolate the vascular progenitor cells (CD34+CD31-) present in the aortic wall .
- the aortas can be digested with a collagenase-dispase solution.
- the resulting cell suspension was analyzed for the presence of CD34+CD31- cells by reaction with antibodies which specifically recognize these surface antigens .
- the suspension may be incubated with magnetic CD31-antibody-coated beads to remove differentiated endothelial cells, and then with beads coated with an antibody against CD34.
- EBM basal endothelial medium
- FCS foetal calf serum
- FCS endothelial cell-growth supplement
- CD34+/CD31- cells were seeded and cultured for 7 to 10 days in the same conditions described above. The cells were then detached with trypsin and incubated with anti-CD31-coated beads.
- CD34+/CD31+ cells were also able to form a net of capillary-like structures after incubation for 24 hours .
- a further subject of the invention is therefore mature human endothelial cells as defined in Claim 8.
- the Applicant used the aortic ring assay (Nicosia and Ottinetti, 1990) to analyze the vasculogenesis properties of 10 to 12 week-old human embryonic aortae .
- the present invention describes the ex vivo formation of human m crovessels by vasculogenesis for the first time.
- the Applicant's data also indicate that the process of endothelial cell (EC) differentiation in human beings is different from that which occurs with the use of mouse embryonic stem cells. Indeed, in contrast with mouse stem cells, the acquisition of CD31 antigen in human vasculogenesis occurs after the maturation of CD34+ cells in culture. Furthermore, the Applicant's findings indicate that the human embryonic aorta is a rich source of CD34+/CD31- vascular progenitor cells (angioblasts) which are localized all along the external layer of the aorta mesenchyme, probably in close contact with the para-aortic tissue which, at this stage of development, does not contain mature endothelium.
- angioblasts vascular progenitor cells
- the Applicant has found that 20-30% of the CD34+ cells isolated from aorta gave rise to more mature endothelium. The rest of the CD34+ cells have not been investigated. A recent study carried out using mouse embryonic stem cells (Yashmita et al., 2000, Nature 408:92-96) suggested that endothelial and mural cells (pericytes and vascular smooth muscle) may originate from the same Flk-1+ precursors, but it is not known if this process also occurs in human beings. However, the Applicant suggests that, in the embryonic aorta, it may be possible to find and isolate primitive CD34+ Flk-1+ cells that may differentiate into various vascular phenotypes. This may be an important finding because it could lead to the isolation of vascular stem cells and a number of previously published reports have indicated the enormous potential of multipotent stem cells in clinical applications.
- vascular stem cells/angioblasts could be used to investigate the molecular mechanisms involved in human endothelial cell maturation and in vasculogenesis and the Applicant's model may therefore be valuable for vascular regeneration studies.
- these cells offer an important alternative for the clinical treatment of ischaemia and other vascular diseases and suggest possibilities for tissue bioengineering applications and gene therapy.
- the CD34+/CD31- vascular progenitor cells of the present invention may be used in a series of medical applications which may be summarized schematically as follows: - neovascularization of ischaemic tissues, as a result of thrombotic or traumatic phenomena,
- medullary stem cells and those of other origin (such as neuronal stem cells) to promote establishment and growth
- the human embryonic aortas (10-12 weeks) were washed carefully with PBS (phosphate buffer saline) and cleaned of para-aortic material, taking great care not to damage the aorta walls. With the use of a dissection microscope, the aortas were cut transversely with a scalpel so as to produce numerous rings about 1 mm thick. The material thus obtained was stored in DMEM (Dulbecco Modified Eagle Medium) at 4°C for no longer than 2-4 hours before use.
- DMEM Dynamic Eagle Medium
- foetal aorta explants possess the property of forming new cord structures which are composed of cells that express markers typical of differentiated endothelial cells (CD31, CD34, Flk-l/kDR, vWF) , whilst maintaining an apparent state of morphological immaturity, as is clear from a careful ultrastructural examination (see the section on "Characterization of vascular-like cords"), thus suggesting that the vascular structures originating from the cultures of the aortic rings are vessels formed by means of a differentiational/vasculogenetic process, rather than an angiogenetic process (that is, deriving from differentiated/mature endothelial cells pre-existing in the aorta lumen) .
- angiogenetic process that is, deriving from differentiated/mature endothelial cells pre-existing in the aorta lumen
- vascular progenitor cells angioblasts
- angioblasts vascular progenitor cells
- PECAM CD31 membrane antigen
- CD34 also represents a marker of stem cells of other tissue origin, such as, for example the bone marrow
- vWF Factor VIII
- the aorta pellet thus obtained was washed with phosphate buffer saline (PBS) and resuspended in 1 ml of DMEM containing 0.2% of BSA (bovine serum albumin) .
- the aorta cells were then counted: usually about 1.2 x 10 6 were obtained per aorta.
- Phenotype analysis by cytofluorimetry generally showed a presence of about 1-3% of CD31+CD34- cells and a percentage of about 30-40% of CD34+CD31- cells.
- the cell suspension was then used to isolate the vascular precursors.
- the isolation of the endothelial progenitor cells was performed with the use of magnetic beads treated with antibodies which recognize antigens that are present on the precursors and absent in the differentiated cells.
- the cell suspension (about 10 6 cells) was initially incubated (30' at 4°C on a rotary stirrer) (ratio of cells/beads 1:1) with beads (10 6 ) treated with antibodies against CD31 (DAKO, Carpinteria, California) . All of the mature endothelial cells which expressed CD31 bound to the beads and could be removed from the other cells by means of a magnet (Dynal, Oslo, Norway) . It was thus possible to remove all of the CD31+ cells present from the cell suspension (the separation procedure may be repeated several times) .
- the remaining cells were then incubated with further magnetic beads treated with antibodies which recognize CD34 or the antigen AC133 (which is also expressed on the endothelial precursors but absent on the mature endothelium) .
- the cells which bound to the CD34 or AC133 could easily be recovered by means of a magnet.
- the percentage of CD34+AC133+ cells which could be recovered from about 10 6 aorta cells was about 30- 40%, which percentages are similar to those quantified in the cell suspension by flow cytofluorimetry.
- the cell suspension obtained was filtered with filters with 10 ⁇ m porosity to remove all of the cell aggregates which were not completely broken up, whilst the individual cells in suspension were recovered and washed with PBS. The cells obtained were then incubated for 30' at 4°C with Milteni anti-AC133 magnetic micro-beads with a quantity equal to about 100 ⁇ l per 10 8 isolated cells.
- the AC133+ cells were therefore incubated with magnetic beads (Dynal, Oslo, Norway) treated with antibodies which recognize CD34 (this antigen is expressed on the vascular precursors and also on the mature endothelial cells) .
- This step enabled the AC133+CD34+ cells to be separated from the AC133+CD34- cells and an almost pure population of vascular progenitor cells thus to be obtained.
- the percentages of CD34-positive, AC133 -positive, and CD34+AC133+ doubly positive cells recovered per 10 6 cells evaluated were 27%, 10% and 3%, respectively, for digested foetal liver and 35%, 7% and 1.3% for heart.
- the percentages of CD34+AC133+ cells in the AC133+ population were of the order of 30% for liver and 13% for heart .
- Some of the cells separated by the magnetic beads which bound CD34 or AC133 were characterized phenotypically to further check the absence of CD31 and vWF.
- An aliquot of purified cells (about 10 4 ) was seeded on glass slides treated with a collagen solution and fibronectin (as described by Alessandri et al Lab. Invest. 1998, 78:127-128) and left to incubate at 37°C for about 24 hours in a culture medium composed of EBM (endothelium basal medium, BioWhittaker, Walkersville, Maryland) containing 10% of FCS (foetal calf serum) .
- EBM endothelium basal medium, BioWhittaker, Walkersville, Maryland
- FCS farnesoetal calf serum
- the adherent cells were fixed with 4% paraformaldehyde in PBS, pH 7.4 for 10' at room temperature. 2-3 washings with PBS (0.1% Triton-X) were followed by a washing with a 10% guinea-pig serum medium (NGS) (Gibco, Grand Island, New York) .
- NGS guinea-pig serum medium
- the glass slides were then incubated with mouse anti-human CD31 monoclonal antibody or anti-human vWF (used at dilutions of 1:100 and 1:80, respectively) (purchased from Sigma, St. Louis, Missouri) for about 90' at 37°C.
- the cells were incubated with a solution (1:300) of cyanine dye- labelled goat anti-mouse or anti-rabbit immunoglobulin G (IgG) (Cy2, Jackson Immunoresearch, Pennsylvania), respectively, for about 45' at room temperature. After drying of the preparation in air, the fluorescent cells were displayed and photographed with a Zeiss Axiophot-2 microscope (Zeiss, Oberkochen, Germariy) . Generally, after immunocytochemical analysis, less than 19% of the CD34+/AC133+ cells were CD31 positive and 0% were positive to vWF within 24 hours after seeding.
- the cells were cultured in a medium which induced differentiation of the CD34+ progenitor cells into mature endothelial cells.
- the differentiation medium (M-2) was composed of the following components: MI 99 (Gibco) , containing 20% of FCS, 10% of Condimed (Boehringer, Mannheim, ⁇ Germany) , heparin (lO ⁇ g/ml) (Sigma) , basic fibroblast growth factor (bFGF) (20ng/ml) (Sigma) , plus vascular endothelial growth factor (VEGF) (5ng/ml) (R&D System, Inc., Minneapolis, MN) .
- the CD34+/AC133+ cells were seeded in plastics cell-culture flasks treated with type I collagen (Calf Skin, Boehring, Mannheim, Germany) l ⁇ g/cm 2 and bovine plasmatic fibronectin (SIGMA) l ⁇ g/cm 2 . After adhesion, the cells were cultured at 37°C in 5% C0 2 with M-2 for about 5-7 days. Upon completion of the incubation, the cells were detached from the plastics with trypsin, washed with PBS and counted. The cells were then incubated (procedure as described above) with anti-CD31 magnetic beads to isolate the mature endothelial cells. Generally, about 25-35% of the CD34+CD31- cells initially seeded differentiated into CD34+CD31+/vWF+ .
- type I collagen Calf Skin, Boehring, Mannheim, Germany
- SIGMA bovine plasmatic fibronectin
- endothelial cell cultures derived by differentiation in vitro from foetal aorta vascular progenitor cells expressed some classical phenotypical and functional features of cultures of mature endothelial cells isolated both from foetal tissues and from adult human tissues.
- endothelial cells when cultured on Matrigel (Necton-Dickinson, Bedford, Massachusetts) , they were able to form capillary structures similar to human capillary vessels in vitro. This ability to form vascular-like structures in vitro is a very specific property of endothelial cells.
- the CD34+AC133+ cells from aorta explants can be amplified in vitro by ,culture in a culture medium which keeps some of them in the state of immature cells.
- the culture medium defined as "medium-6" (M-6) is composed of the following elements: EBM medium + 10% FCS + 10% Condimed + 10% H-I (hormone mix; 400 ml of H-I are composed of: 40 ml of DMEM/F12 10X, 8 ml of 30% glucose, 6 ml of 7.5% Na 2 HC0 3 , 2 ml of 1M HEPES, 322 ml of sterile apyrogenic H 2 0, 400 mg of apotransferrin (SIGMA) , 100 mg of insulin (Sigma) dissolved in 2 ml of 0.1 N HCl, 38,64 mg of putrescine (Sigma), 40 ⁇ l of 3xlO "3 M selenium (Sigma) , 40 ⁇ l of 2xlO "3
- CD34+ cells kept in M-6 retain properties of immature cells (CD34+CD31-) for at least 3 weeks of culture. After this period, a progressive percentage (50%) of CD34+ loses this antigen and is no longer able to differentiate into mature endothelium, whereas the remaining percentage retains the ability to differentiate. Up to now, it is not known to what extent it is possible to keep the CD34+ in the undifferentiated form.
- Liver and heart AC133+CD34+ cells can be amplified in culture in a manner similar to that already described for the aorta.
- the culture medium for the expansion of the vascular progenitor cells from liver and heart is preferably composed of medium 199 supplemented with 10% FCS, 10% Condimed (Boehringer, Mannheim) 20 ng/ml bFGF, 20 ⁇ g/ml heparin, and 10% hormone mix.
- Many CD34+AC133+ cells kept in this medium retain properties of immature cells, remaining negative to CD31 (markers of acquisition of endothelial maturity) for several weeks.
- CD31 spontaneously and can be separated with the aid of magnetic beads treated with anti-CD31 antibodies in order to be cultured separately (for example, to develop a culture of mature endothelial cells) .
- This ability to differentiate spontaneously into mature endothelial cells persists for at least 3-4 generations (about 4-5 weeks of culture) after which many of the initial CD34+AC133+ cells tend to lose both the markers which characterize them and the ability to differentiate into mature endothelium.
- Flow cytofluorimetry analysis was performed on the total mixed cell population obtained by collagenase-dispase digestion of the aortic fragment. About 1 x 10 5 cells were collected, stained and incubated in the dark for 30 minutes at 4°C with fluoresceinated (FITC) anti-CD34 antibody and with anti-CD31 phycoerythrinated (PE) antibody (Beeton Dickinson, San Jose, California( dilution 1:10). After two washings with PBS, the cells were analyzed by flow cytofluorimetry with the use of a FACSscan (Becton Dickinson, Mountain View, California) .
- FITC fluoresceinated
- PE phycoerythrinated
- Formalin-fixed tissues were included in paraffin following standard histology techniques .
- Four-micrometer serial sections were transferred to glass slides coated with poly- lysine and rehydrated by immersion in 100% xylene and in a series of ethanol solutions of decreasing concentration (100%, 95%, 90%, 80% and 70%) .
- the sections were then heat- treated in a microwave cooker to enhance antigenicity and allow epitope unmasking: twice for 5 minutes each in ImM EDTA pH8, for CD31, CD34 and vWF antigens, and three times for 4 minutes each in 0.01M citrate buffer pH6 for the Flk-1 antigen. Endogenous peroxidases were inhibited for 15 minutes at room temperature with 3% hydrogen peroxide.
- the sections were incubated for 30 minutes with the anti-immunoglobulin antibodies of species conjugated to biotin and processed according to the avidin/biotin peroxidase complex method with kit reagents (mouse IgG and rabbit IgG Vectastain; Vector Laboratories, Burlingane, California) .
- kit reagents mouse IgG and rabbit IgG Vectastain; Vector Laboratories, Burlingane, California
- Peroxidase activity was shown with 3 , 3 ' -diaminobenzidine (Menarini-Biogenex, San Ramon, California) in PBS and staining with haematoxylin- eosin. To exclude false positives produced by non-specific binding of the secondary antibody, all of the tissues were treated in the same manner with buffer substituting for the primary antibody.
- Selected cultured explants were fixed in 2.5% glutaraldehyde immediately after preparation, postfixed in osmium tetroxide, embedded in Epon-Aaraldite and observed under a Zeiss CEM 902 microscope .
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002314526A AU2002314526A1 (en) | 2001-05-31 | 2002-05-30 | Human vascular progenitor cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITTO2001A000517 | 2001-05-31 | ||
IT2001TO000517A ITTO20010517A1 (en) | 2001-05-31 | 2001-05-31 | HUMAN VASCULAR PROGENITRIC CELLS. |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002097066A2 true WO2002097066A2 (en) | 2002-12-05 |
WO2002097066A8 WO2002097066A8 (en) | 2003-03-13 |
WO2002097066A3 WO2002097066A3 (en) | 2003-09-25 |
Family
ID=11458912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2002/000347 WO2002097066A2 (en) | 2001-05-31 | 2002-05-30 | Human vascular progenitor cells |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002314526A1 (en) |
IT (1) | ITTO20010517A1 (en) |
WO (1) | WO2002097066A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006020954A1 (en) * | 2004-08-13 | 2006-02-23 | Medtronic, Inc. | Isolation of endothelial progenitor cell subsets and methods for their use |
WO2008008229A3 (en) * | 2006-07-10 | 2008-09-18 | Univ Columbia | De novo formation and regeneration of vascularized tissue from tissue progenitor cells and vascular progenitor cells |
WO2010006219A2 (en) * | 2008-07-09 | 2010-01-14 | Baxter International Inc. | Use of scaffold comprising fibrin for delivery of stem cells |
US7794705B2 (en) | 2005-11-07 | 2010-09-14 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
US8071380B2 (en) | 2006-02-16 | 2011-12-06 | Fondazione Centro San Raffaele Del Monte Tabor | Skeletal muscle periangioblasts and cardiac mesangioblasts, method for isolation and uses thereof |
US8343485B2 (en) | 2005-11-07 | 2013-01-01 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
US8425899B2 (en) | 2005-11-07 | 2013-04-23 | Andrew L. Pecora | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
US9034316B2 (en) | 2006-10-24 | 2015-05-19 | Amorcyte, Llc | Infarct area perfusion-improving compositions and methods of vascular injury repair |
-
2001
- 2001-05-31 IT IT2001TO000517A patent/ITTO20010517A1/en unknown
-
2002
- 2002-05-30 WO PCT/IT2002/000347 patent/WO2002097066A2/en not_active Application Discontinuation
- 2002-05-30 AU AU2002314526A patent/AU2002314526A1/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
ALESSANDRI GIOLIO ET AL: "Outgrowth of branching microvessels from human fetal aorta explants in vitro: An angiogenesis and vasculogenesis process." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03), page 650 XP002227165 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000 ISSN: 0197-016X * |
ALESSANDRI GIULIO ET AL: "Human vasculogenesis ex vivo: Embryonal aorta as a tool for isolation of endothelial cell progenitors." LABORATORY INVESTIGATION, vol. 81, no. 6, June 2001 (2001-06), pages 875-885, XP002227166 ISSN: 0023-6837 * |
ALESSANDRI GIULIO ET AL: "Isolation of vascular progenitors from human embryonal aorta." JOURNAL OF HUMAN VIROLOGY, vol. 4, no. 3, May 2001 (2001-05), page 146 XP001122836 2001 International Meeting of the Institute of Human Virology;Baltimore, Maryland, USA; September 09-13, 2001 ISSN: 1090-9508 * |
GIRELLI M ET AL: "Human embryonic endothelial cells: a new tool for therapeutical approach in neurological disorders?" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, pages Abstract No.-327.14, XP001109455 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000 ISSN: 0190-5295 * |
HEWETT P W ET AL: "Human lung microvessel endothelial cells: Isolation, culture, and characterization." MICROVASCULAR RESEARCH, vol. 46, no. 1, 1993, pages 89-102, XP008012295 ISSN: 0026-2862 * |
MASUDA H ET AL: "Endothelial progenitor cells for regeneration." HUMAN CELL: OFFICIAL JOURNAL OF HUMAN CELL RESEARCH SOCIETY. JAPAN DEC 2000, vol. 13, no. 4, December 2000 (2000-12), pages 153-160, XP001133828 ISSN: 0914-7470 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006020954A1 (en) * | 2004-08-13 | 2006-02-23 | Medtronic, Inc. | Isolation of endothelial progenitor cell subsets and methods for their use |
US7794705B2 (en) | 2005-11-07 | 2010-09-14 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
US8088370B2 (en) | 2005-11-07 | 2012-01-03 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
US8343485B2 (en) | 2005-11-07 | 2013-01-01 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
US8425899B2 (en) | 2005-11-07 | 2013-04-23 | Andrew L. Pecora | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
US8637005B2 (en) | 2005-11-07 | 2014-01-28 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
US9534202B2 (en) | 2005-11-07 | 2017-01-03 | Amorcyte, Inc. | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
US8071380B2 (en) | 2006-02-16 | 2011-12-06 | Fondazione Centro San Raffaele Del Monte Tabor | Skeletal muscle periangioblasts and cardiac mesangioblasts, method for isolation and uses thereof |
WO2008008229A3 (en) * | 2006-07-10 | 2008-09-18 | Univ Columbia | De novo formation and regeneration of vascularized tissue from tissue progenitor cells and vascular progenitor cells |
US9034316B2 (en) | 2006-10-24 | 2015-05-19 | Amorcyte, Llc | Infarct area perfusion-improving compositions and methods of vascular injury repair |
WO2010006219A2 (en) * | 2008-07-09 | 2010-01-14 | Baxter International Inc. | Use of scaffold comprising fibrin for delivery of stem cells |
WO2010006219A3 (en) * | 2008-07-09 | 2010-09-23 | Baxter International Inc. | Use of scaffold comprising fibrin for delivery of stem cells |
Also Published As
Publication number | Publication date |
---|---|
ITTO20010517A0 (en) | 2001-05-31 |
AU2002314526A1 (en) | 2002-12-09 |
ITTO20010517A1 (en) | 2002-12-01 |
WO2002097066A8 (en) | 2003-03-13 |
WO2002097066A3 (en) | 2003-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Alessandri et al. | Human vasculogenesis ex vivo: embryonal aorta as a tool for isolation of endothelial cell progenitors | |
Song et al. | Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions | |
US9867854B2 (en) | Therapeutic method using cardiac tissue-derived pluripotent stem cells | |
Chiavegato et al. | Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat | |
Wang et al. | Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardiomyocyte and smooth muscle cell | |
CA2468171C (en) | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof | |
Deugnier et al. | Isolation of mouse mammary epithelial progenitor cells with basal characteristics from the Comma-Dβ cell line | |
US20050079606A1 (en) | Pluripotent stem cells originating in skeletal muscle intestinal tissue | |
JP2002537761A (en) | Transgenic circulating endothelial cells | |
JP4085062B2 (en) | Endothelial cells derived from primate embryonic stem cells | |
Monga et al. | Expansion of hepatic and hematopoietic stem cells utilizing mouse embryonic liver explants | |
KR102251129B1 (en) | Methods and compositions to modulate hair growth | |
JP2005151907A (en) | Human stem cell derived from placenta or amnion and method for establishing the same and method for differentiation-induction to organ | |
He et al. | Differentiation of putative hepatic stem cells derived from adult rats into mature hepatocytes in the presence of epidermal growth factor and hepatocyte growth factor | |
Tamaki et al. | Synchronized reconstitution of muscle fibers, peripheral nerves and blood vessels by murine skeletal muscle-derived CD34−/45− cells | |
Ghionzoli et al. | Human amniotic fluid stem cell differentiation along smooth muscle lineage | |
Lin et al. | Fibroblast growth factor-2 facilitates rapid anastomosis formation between bioengineered human vascular networks and living vasculature | |
Ramsauer et al. | Regulation of a blood-brain barrier—specific enzyme expressed by cerebral pericytes (pericytic aminopeptidase N/pAPN) under cell culture conditions | |
WO2002097066A2 (en) | Human vascular progenitor cells | |
JP2008125540A (en) | Artificial skin | |
KR20120006386A (en) | Stem cell derived from first trimester placenta and cellular therapeutic agents comprising the same | |
US20080241111A1 (en) | Pluripotent Stem Cell Derived from Cardiac Tissue | |
Yu et al. | First trimester placental mesenchymal stem cells improve cardiac function of rat after myocardial infarction via enhanced neovascularization | |
AU2002349641B2 (en) | Stem cells originating in salivary duct epithelial cells and use thereof | |
Giakoumopoulos et al. | Placental-derived mesenchyme influences chorionic gonadotropin and progesterone secretion of human embryonic stem cell-derived trophoblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |